Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

Alimentary Pharmacology & Therapeutics
C MaVipul Jairath

Abstract

Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. To quantify aminosalicylate use in CD clinical trials, identify factors associated with use and estimate direct annual treatment costs of therapy. MEDLINE, Embase and CENTRAL were searched to April 2017 for placebo-controlled trials in adults with CD treated with corticosteroids, immunosuppressants or biologics. The proportion of patients co-prescribed aminosalicylates in placebo arms was pooled using a random-effects model. Meta-regression was used to identify factors associated with aminosalicylate use. Annual treatment costs were estimated using the 2016 Ontario Drug Benefit Program. Forty-two induction and 10 maintenance trials were included. The pooled proportion of patients co-prescribed aminosalicylates was 44% [95% CI: 39%-49%] in induction trials and 49% [95% CI: 35%-64%] in maintenance trials. There was substantial to considerable heterogeneity (I2  = 86.0%, 91.8% for induction and maintenance trials, respectively). In multivariable meta-regression, aminosalicylate use has decreased over time in induction trials (OR 0.50 [95% CI: ...Continue Reading

References

Sep 28, 1989·The New England Journal of Medicine·J BrynskovM C Campanini
Mar 8, 1980·Lancet·R F Harvey, J M Bradshaw
Apr 21, 2001·Gastroenterology·W J SandbornUNKNOWN CDP571 Crohn's Disease Study Group
Mar 6, 2002·Alimentary Pharmacology & Therapeutics·B E SandsUNKNOWN RHIL-11 Crohn's Study group
Jan 3, 2003·The New England Journal of Medicine·Subrata GhoshUNKNOWN Natalizumab Pan-European Study Group
Feb 27, 2004·The New England Journal of Medicine·Bruce E SandsSander J van Deventer
May 1, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G Feagan
May 1, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stephen B Hanauer, Ulf Strömberg
Nov 13, 2004·The New England Journal of Medicine·Peter J MannonUNKNOWN Anti-IL-12 Crohn's Disease Study Group
May 27, 2005·The New England Journal of Medicine·Joshua R KorzenikUNKNOWN Sargramostim in Crohn's Disease Study Group
Sep 7, 2005·Gastroenterology·Stefan SchreiberUNKNOWN CDP870 Crohn's Disease Study Group
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Sep 6, 2006·Gastroenterology·Selwyn OdesUNKNOWN European Collaborative Study on Inflammatory Bowel Disease
Jan 9, 2007·Inflammatory Bowel Diseases·Jonathan P TerdimanDavid T Rubin
May 2, 2007·Annals of Internal Medicine·William J SandbornPaul F Pollack
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Aug 19, 2008·Gastroenterology·William J SandbornUNKNOWN Ustekinumab Crohn's Disease Study Group
Oct 3, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G FeaganAsit Parikh
Jan 29, 2009·The American Journal of Gastroenterology·Gary R LichtensteinUNKNOWN Practice Parameters Committee of American College of Gastroenterology
Aug 26, 2009·Digestive Diseases and Sciences·Jeffrey TangAnn L Silverman
Dec 3, 2010·Journal of Crohn's & Colitis·A DignassUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Mar 17, 2011·The American Journal of Gastroenterology·Charles N BernsteinJames F Blanchard
Feb 14, 2012·Journal of Crohn's & Colitis·Mamoru WatanabeUNKNOWN Study Investigators

❮ Previous
Next ❯

Citations

May 20, 2020·Alimentary Pharmacology & Therapeutics·Barbara ScrivoAmbrogio Orlando
Dec 28, 2018·Alimentary Pharmacology & Therapeutics·J Mansfield, L MacDougall
Nov 20, 2021·Digestive Diseases and Sciences·Dominic PicettiSiddharth Singh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.